Using an onset-anchored Bayesian hierarchical model to improve predictions for amyotrophic lateral sclerosis disease progression by Alex G. Karanevich, Jeffrey M. Statland, Byron J. Gajewski, Jianghua He

Get full text

Using automated electronic medical record data extraction to model ALS survival and progression by Alex G. Karanevich, Luke J. Weisbrod, Omar Jawdat, Richard J. Barohn, Byron J. Gajewski, Jianghua He, Jeffrey M. Statland

Get full text

Phenotypic diversity in an international Cure VCP Disease registry by Chiseko Ikenaga, Andrew R. Findlay, Michelle Seiffert, Allison Peck, Nathan Peck, Nicholas E. Johnson, Jeffrey M. Statland, Conrad C. Weihl

Get full text

Patient reported impact of symptoms in amyotrophic lateral sclerosis (PRISM-ALS): A national, cross-sectional studyResearch in context by Christine Zizzi, Jamison Seabury, Spencer Rosero, Danae Alexandrou, Ellen Wagner, Jennifer S. Weinstein, Anika Varma, Nuran Dilek, John Heatwole, Joanne Wuu, James Caress, Richard Bedlack, Volkan Granit, Jeffrey M. Statland, Paul Mehta, Michael Benatar, Chad Heatwole

Get full text

Stabilization of Early Duchenne Cardiomyopathy With Aldosterone Inhibition: Results of the Multicenter AIDMD Trial by Subha V. Raman, Kan N. Hor, Wojciech Mazur, Andrea Cardona, Xin He, Nancy Halnon, Larry Markham, Jonathan H. Soslow, Michael D. Puchalski, Scott R. Auerbach, Uyen Truong, Suzanne Smart, Beth McCarthy, Ibrahim M. Saeed, Jeffrey M. Statland, John T. Kissel, Linda H. Cripe

Get full text

Correction to: A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot–Marie–Tooth type 1A by Shahram Attarian, Peter Young, Thomas H. Brannagan, David Adams, Philip Van Damme, Florian P. Thomas, Carlos Casanovas, Jafar Kafaie, Céline Tard, Maggie C. Walter, Yann Péréon, David Walk, Amro Stino, Marianne de Visser, Camiel Verhamme, Anthony Amato, Gregory Carter, Laurent Magy, Jeffrey M. Statland, Kevin Felice

Get full text

A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot–Marie–Tooth type 1A by Shahram Attarian, Peter Young, Thomas H. Brannagan, David Adams, Philip Van Damme, Florian P. Thomas, Carlos Casanovas, Jafar Kafaie, Céline Tard, Maggie C. Walter, Yann Péréon, David Walk, Amro Stino, Marianne de Visser, Camiel Verhamme, Anthony Amato, Gregory Carter, Laurent Magy, Jeffrey M. Statland, Kevin Felice

Get full text

Clinical trial readiness to solve barriers to drug development in FSHD (ReSolve): protocol of a large, international, multi-center prospective study by Samantha LoRusso, Nicholas E. Johnson, Michael P. McDermott, Katy Eichinger, Russell J. Butterfield, Elena Carraro, Kiley Higgs, Leann Lewis, Karlien Mul, Sabrina Sacconi, Valeria A. Sansone, Perry Shieh, Baziel van Engelen, Kathryn Wagner, Leo Wang, Jeffrey M. Statland, Rabi Tawil, on behalf of the ReSolve Investigators and the FSHD CTRN18

Get full text

Machine learning suggests polygenic risk for cognitive dysfunction in amyotrophic lateral sclerosis by Katerina Placek, Michael Benatar, Joanne Wuu, Evadnie Rampersaud, Laura Hennessy, Vivianna M Van Deerlin, Murray Grossman, David J Irwin, Lauren Elman, Leo McCluskey, Colin Quinn, Volkan Granit, Jeffrey M Statland, Ted M Burns, John Ravits, Andrea Swenson, Jon Katz, Erik P Pioro, Carlayne Jackson, James Caress, Yuen So, Samuel Maiser, David Walk, Edward B Lee, John Q Trojanowski, Philip Cook, James Gee, Jin Sha, Adam C Naj, Rosa Rademakers, The CReATe Consortium, Wenan Chen, Gang Wu, J Paul Taylor, Corey T McMillan

Get full text